In 2017, fucoxanthin (57, Figure 17), a well-known marine carotenoid, was shown to inhibit Akt/NF-κB and involved MAPK pathways in vitro, suggesting that it could be a potential therapeutic agent acting by this mechanism for the therapy of neurodegenerative diseases [71,72,73]. The gene discussed is AKT1; the disease is neurodegenerative disease.